

RECEIVED

DEC 11 2001

PATENT
TECH CENTER 1600/2900

DOCKET NO.: TJU-2503 (SCH01.NP001)

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP NO. 1635

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Schneider

Serial No.: 09/435,249

Group Art Unit: 1635

Filed: November 5, 1999

Examiner: M. Schmidt

For: Treatment Of Parkinson's Disease With Oligonucleotides

EXPRESS MAIL INFORMATION

EXPRESS MAIL LABEL NO: EL568091808US

DATE OF DEPOSIT: November 13, 2001

BOX AF

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT AND REQUEST FOR RECONSIDERATION

In response to the Office Action mailed August 13, 2001 in connection with the above-identified patent application, Applicant requests that the application be amended as follows.

In the Claims:

Please cancel claims 5-8 and 13-22 without prejudice to their presentation in another application; add new claims 23-33; and amend claims 1 and 9 to read as follows:

- B²
1. (Amended) A method of treating Parkinson's disease in a mammal, comprising administering a therapeutically effective amount of antisense oligonucleotide comprising SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5 to the substantia nigra pars reticulata via a cannula for the downregulation of glutamic acid decarboxylase.